News coverage about SciClone Pharmaceuticals (NASDAQ:SCLN) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.3840144083803 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

SciClone Pharmaceuticals (NASDAQ SCLN) opened at $11.15 on Thursday. SciClone Pharmaceuticals has a 52 week low of $8.55 and a 52 week high of $11.43. The company has a market cap of $581.94 and a PE ratio of 12.97.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/sciclone-pharmaceuticals-scln-receives-daily-media-impact-rating-of-0-17/1786171.html.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.